ClinicalTrials.gg
RecruitingNCT07400419STRENGTHUpdated Sep 11, 2026

Effects of Resistance Exercise Among TGD Individuals Initiating Estrogen-Based Gender-Affirming Hormone Therapy

An interventional study of Resistance Exercise Program and Nutrition and Exercise Counseling in Muscle Mass and Strength, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies in Sarcopenia with a site in United States — 36 open to participants now, 46 under way, 1 of them phase 3. Sarcopenia · United States.

Planned enrollment
73rd of 146
40 · median 40
Started
2026
with 13 others
No phase
101 of 187
18 open now
Primary completion
2028-04
later than 35 of 45 live
Registered
177th of 187
by date

Among the 187 studies in Sarcopenia with a site in United States, this one is the 73rd largest by planned enrollment of the 146 interventional ones that give a count, is one of 14 that started in 2026, is one of 101 with no phase, reaches primary completion later than 35 of the 45 other live ones, and was the 177th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

36 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Sarcopenia with a site in United States, or all of them as a file.
02

Study summary

Estrogen-dominant gender-affirming hormone therapy (GAHT) is standard of care for transgender women and gender-diverse individuals and typically consists of estrogen together with anti-androgen/ testosterone therapy. Estrogen and testosterone balance influences fat and muscle mass, muscular strength and the development of sarcopenia. Sarcopenia, a condition characterized by the loss of muscular mass, strength, and function, in turn, is associated with increased mortality and adverse health outcomes. Estrogen-dominant GAHT may have deleterious effects on body composition and muscular performance that place TGD individuals at-risk for sarcopenia. As part of NCT04128488, our investigative team found that appendicular lean mass (ALM)/ height2 decreases after estrogen-based GAHT, thereby portending a higher risk for sarcopenia after GAHT. Early recognition of the changes in body composition and muscular performance leading to sarcopenia are critical, providing potential avenues to intervene and abrogate untoward downstream health effects. A promising intervention is resistance exercise, which has been shown in select populations to improve muscular mass and strength and reduce fat mass, and, thus, mitigate progression to sarcopenia in at-risk populations. For this prospective, pilot clinical trial, investigators will enroll participants who are about to be initiated or recently initiated (3 months ago or less) on estrogen-dominant gender-affirming hormone therapy. Investigators will be randomizing participants 1:1 to either an at-home resistance exercise intervention or no exercise intervention (nutritional and exercise counseling only) for 12 weeks and assess muscle mass, strength, and function both before and after this 12-week period. The exercise intervention group will be provided with the necessary materials to complete the exercise program along with weekly virtual visits with our study team in order to learn their assigned exercises for the week. Further, survey tools will be administered to ascertain whether the resistance exercise intervention may affect gender congruence.

03

Conditions studied

  • Muscle Mass and Strength

Browse trials for

Keywords

  • Transgender women
  • Gender-Diverse
  • Estrogen-dominant gender-affirming hormone therapy
  • Sarcopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years
  • Initiating or within 3 months or less of initiating GAHT with estradiol (oral, sublingual, patch, injection) AND androgen suppression (leuprolide, spironolactone or bicalutamide)
  • Identifies as either a transgender female/woman, gender-diverse, non-binary, gender non-confirming, gender-fluid, and/or gender-queer
  • Assigned male sex at birth

Exclusion criteria

Exclusion Criteria:

  • Current condition(s) which may preclude the ability to participate in a resistance exercise program (including but not limited to conditions which may significantly impair mobility and balance)
  • Current condition(s) where resistance exercise program may be (including but not limited to decompensated heart failure, unstable ischemic heart disease, pulmonary hypertension, aortic aneurysm, moderate to severe valvopathies, and/or moderate to severe chronic respiratory insufficiency)
  • Use of testosterone therapy for > 1 month in the last 6 months
  • Use of gender-affirming hormone therapy with androgen/testosterone suppression and/or estradiol therapy within 1 year of enrollment
  • Use of gender-affirming hormone therapy with androgen/testosterone suppression and/or estradiol therapy for > 1 year at any time period prior to enrollment
  • History of an orchiectomy
  • Current resistance exercise (including but not limited to use of resistance bands, suspension equipment, body weight exercise, free weight exercise) of 60 minutes or greater per week
  • Enrollment in another study that the study investigators deem as potentially interfering with study participants or study endpoints
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Resistance Exercise Intervention

    Participants in this arm will be randomized to a 12-week at-home resistance exercise program.

    Behavioral: Resistance Exercise Program · Behavioral: Nutrition and Exercise Counseling

  • Placebo comparator
    No exercise intervention

    Participants in this arm will receive educational counseling on nutrition and exercising.

    Behavioral: Nutrition and Exercise Counseling

Interventions

  • BehavioralResistance Exercise Program

    Participants will initiate this program within approximately 3 months of starting their gender-affirming hormone therapy and will be instructed to complete resistance exercises for three 60-minute sessions per week for 12 weeks. Participants will have a weekly video call to demonstrate the exercises for that week, have a supervised training session to ensure exercises are performed safely and as instructed, monitor their continued participation in the intervention, and address any questions/issues that arise as part of the program. Participants will be provided with resistance bands, a TRX suspension trainer, and dumbbell weights in order to complete the resistance exercises for the program. Examples of how each exercise can be modified depending on a participant's limitations will also be provided as needed. The study team will ascertain whether they can progress to the next week's exercises depending on their ability to achieve the number of repetition's of the prior week.

  • BehavioralNutrition and Exercise Counseling

    Participants will undergo lifestyle counseling related to optimization of their nutrition and exercise regimen.

06

What researchers measure

Primary outcomes

  1. Appendicular lean mass/height^2

    Change in appendicular lean mass/height\^2 (kg/m\^2) assessed via whole body DEXA in resistance exercise group

    Time frame: 12 weeks

  2. Gender congruence

    Change in gender congruence (utilizing the total scale score from Transgender Congruence Scale) in resistance exercise group

    Time frame: 12 weeks

Secondary outcomes

  1. Visceral adipose tissue mass

    Change in total visceral adipose tissue mass (g) assessed using whole body DEXA in resistance exercise group

    Time frame: 12 weeks

  2. Visceral adipose tissue volume

    Change it total visceral adipose tissue volume (cm3) assessed using whole body DEXA in resistance exercise group

    Time frame: 12 weeks

  3. Total fat mass

    Change in total fat mass (kg) assessed using whole body DEXA in resistance exercise group

    Time frame: 12 weeks

  4. Total lean body mass

    Change in total lean body mass (kg) assessed using whole body DEXA in resistance exercise group

    Time frame: 12 weeks

  5. Muscular function

    Change in muscular function assessed via the 5 X sit to stand test (sec) in resistance exercise group

    Time frame: 12 weeks

  6. Hand-grip strength

    Change in hand-grip strength (kg) assessed using a Lafayette Hand Grip Dynamometer in resistance exercise group

    Time frame: 12 weeks

  7. Horizontal shoulder adduction strength

    Change in horizontal shoulder adduction strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group

    Time frame: 12 weeks

  8. Shoulder extension strength

    Change in shoulder extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group

    Time frame: 12 weeks

  9. Elbow flexion strength

    Change in elbow flexion strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group

    Time frame: 12 weeks

  10. Elbow extension strength

    Change in elbow extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group

    Time frame: 12 weeks

  11. Knee extension strength

    Change in knee extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group

    Time frame: 12 weeks

  12. Knee flexion strength

    Change in knee flexion strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group

    Time frame: 12 weeks

  13. Hip extension strength

    Change in hip extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group

    Time frame: 12 weeks

  14. Resting energy expenditure

    Change in resting energy expenditure (kcal/day) assessed using a metabolic cart in the resistance exercise group

    Time frame: 12 weeks

  15. Resting metabolic rate

    Change in resting metabolic rate (kcal/day) assessed using a metabolic cart in resistance exercise group

    Time frame: 12 weeks

  16. Respiratory quotient

    Change in respiratory quotient (ratio) assessed using a metabolic cart in the resistance exercise group

    Time frame: 12 weeks

  17. Between-group change in appendicular lean body mass/ height^2

    Between-group change in appendicular lean body mass/ height\^2 (kg/m\^2) assessed via whole body DEXA

    Time frame: 12 weeks

  18. Between-group change in total visceral adipose tissue mass

    Between-group change in total visceral adipose tissue mass (g) assessed using whole body DEXA

    Time frame: 12 weeks

  19. Between-group change in visceral adipose tissue volume

    Between-change in total visceral adipose tissue volume (cm3) assessed using whole body DEXA

    Time frame: 12 weeks

  20. Between-group change in total fat mass

    Between-change in total fat mass (kg) assessed using whole body DEXA

    Time frame: 12 weeks

  21. Between-group change in total lean body mass

    Between-group change in total lean body mass (kg) assessed using whole body DEXA

    Time frame: 12 weeks

  22. Between-group change in muscular function via the 5x sit to stand test

    Between-group change in muscular function assessed via the 5 X sit to stand test (sec)

    Time frame: 12 weeks

  23. Between-group change in hand-grip strength

    Between-group change in hand-grip strength (kg) assessed using a Lafayette Hand Grip Dynamometer

    Time frame: 12 weeks

  24. Between-group change in horizontal shoulder adduction strength

    Between-group change in horizontal shoulder adduction strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer

    Time frame: 12 weeks

  25. Bwtween-group change in shoulder extension strength

    Between-group change in shoulder extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer

    Time frame: 12 weeks

  26. Between-group change in elbow flexion strength

    Between-group change in elbow flexion strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer

    Time frame: 12 weeks

  27. Between-group change in elbow extension strength

    Between-group change in elbow extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer

    Time frame: 12 weeks

  28. Between-group change in knee extension strength

    Between-group change in knee extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer

    Time frame: 12 weeks

  29. Between-group change in knee flexion strength

    Between-group change in knee flexion strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer

    Time frame: 12 weeks

  30. Between-group change in hip extension strength

    Between-group change in hip extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer

    Time frame: 12 weeks

  31. Between-group change in resting energy expenditure

    Between-group change in resting energy expenditure (kcal/day) assessed using a metabolic cart

    Time frame: 12 weeks

  32. Between-group change in resting metabolic rate

    Between-group change in resting metabolic rate (kcal/day) assessed using a metabolic cart

    Time frame: 12 weeks

  33. Between-group change in respiratory quotient

    Between-group change in respiratory quotient (ratio) assessed using a metabolic cart

    Time frame: 12 weeks

  34. Appearance congruence

    Change in appearance congruence (utilizing the appearance congruence subscale score from Transgender Congruence Scale) in resistance exercise group

    Time frame: 12 weeks

  35. Gender identity acceptance

    Change in gender identity acceptance (utilizing the gender identity acceptance subscale score from Transgender Congruence Scale) in resistance exercise group

    Time frame: 12 weeks

  36. Between-group change in appearance congruence

    Between-group change in appearance congruence (utilizing the appearance congruence subscale score from Transgender Congruence Scale)

    Time frame: 12 weeks

  37. Between-group change in gender identity acceptance

    Between-group change in gender identity acceptance (utilizing the gender identity acceptance subscale score from Transgender Congruence Scale)

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 23 months is above that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 10, 2026
StartActual
Apr 16, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Apr 1, 2028
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07400419
Responsible party
Mabel Toribio (Assistant Professor, Massachusetts General Hospital) — Principal investigator
First posted
Feb 10, 2026
Start date
Apr 16, 2026
Primary completion
Apr 1, 2028 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Sep 11, 2026

Study contacts

Mabel Toribio, MD
Contact
mptoribio@mgh.harvard.edu
617-724-2826

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion